Resources

ASK AN EXPERT

Improved COGs with nLiven PR

Chimeric Antigen Receptor T cell (carT) Therapies have shown incredible efficacy against multiple hematological cancers. At present, the majority of both commercially available products and those in clinical trials are autologous by nature. Given the inherent variability of these starting materials, manufacturing processes strive to limit variability from other process inputs such as cell culture reagents. 

View PDF